Related Experiment Videos
A clinical trial with cefoperazone in pneumonia and pyelonephritis
Abstract:
15 cases of pneumonia and 15 cases of pyelonephritis were included in a clinical trial of parenteral cefoperazone. The organisms isolated from patients with bacterial pneumonia were: Staphylococcus aureus (6), Klebsiella pneumoniae (5), Diplococcus pneumoniae (3), Pseudomonas species (2), and 6 others. Amongst those with pyelonephritis, Escherichia coli (12), Enterobacter (1), and 3 other pathogens, were isolated. All were sensitive to cefoperazone. The efficacy of cefoperazone in patients with pneumonia was: good in 11 (73%), fair in 3, and poor in 1. In pyelonephritis, 12 (80%) responded well and in the other 3 response was fair. There were no significant side effects or hypersensitivity reactions.
Insights
Parenteral cefoperazone demonstrated high efficacy in treating bacterial pneumonia and pyelonephritis, with no significant side effects observed. This antibiotic proved effective against common pathogens like Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Bacterial pneumonia and pyelonephritis are significant causes of morbidity.
- Parenteral antibiotics are crucial for treating severe bacterial infections.
- Cefoperazone is a third-generation cephalosporin with broad-spectrum activity.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of parenteral cefoperazone.
- To assess cefoperazone's effectiveness against common pathogens causing pneumonia and pyelonephritis.
Main Methods:
- A clinical trial involving 30 patients (15 pneumonia, 15 pyelonephritis).
- Identification of causative pathogens and susceptibility testing to cefoperazone.
- Assessment of treatment response and monitoring for adverse events.
Main Results:
- Common pathogens included Staphylococcus aureus, Klebsiella pneumoniae, Diplococcus pneumoniae, and Escherichia coli.
- All isolated organisms were sensitive to cefoperazone.
- Good to fair efficacy was observed in 73% of pneumonia cases and 80% of pyelonephritis cases.
- No significant side effects or hypersensitivity reactions were reported.
Conclusions:
- Parenteral cefoperazone is an effective and well-tolerated treatment option for bacterial pneumonia and pyelonephritis.
- Cefoperazone exhibits significant activity against a range of common Gram-positive and Gram-negative pathogens.
- The safety profile supports its use in clinical settings for these infections.